Diabetes and cancer: The mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 5, 2012, Pages 379-387

  Yang, Xilin ^a,b   So, Wing Yee ^a   Ma, Ronald C W ^a   Kong, Alice P S ^a   Xu, Gang ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Cholesterol; Diabetes; Mechanism; Risk factor

Indexed keywords

ADENOSINE PHOSPHATE; APOLIPOPROTEIN A1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE LKB1; RAS PROTEIN; SOMATOMEDIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ALBUMINURIA; BODY MASS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; DISEASE REGISTRY; DRUG USE; ENERGY EXPENDITURE; ENERGY METABOLISM; HUMAN; INSULIN SENSITIVITY; LEUKOCYTE COUNT; LIPID METABOLISM; META ANALYSIS (TOPIC); MOLECULAR INTERACTION; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HONG KONG; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; REGISTRIES;

EID: 84863743325     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2287     Document Type: Review

References (83)

1. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301(20): 2129-40.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2011; 362(12): 1090-101.
3. Greenwood M, Wood F. The relation between the cancer and diabetes death rates. J Hygiene 1914; 14: 83-118. doi:10.1017/S0022172400005702.
4. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273(20): 1605-9.
5. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4(3): 369-80.
6. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50(7): 1365-74.
7. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12): 2819-23.
8. Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 2008; 31(12): 2391-7.
9. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97(22): 1679-87.
10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121(4): 856-62.
11. Jee SH, Park JY, Kim HS, Lee TY, Samet JM. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. Am J Epidemiol 2005; 162(11): 1062-9.
12. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318(19): 1231-9.
13. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008; 4(1): 10-7.
14. Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008; 179(5): 427-37.
15. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how?. Diabetes Obes Metab 2011; DOI: 10.1111/j.1463-1326.2011.01551.x.
16. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-20.
17. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150(4): 327-33.
18. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycaemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 2010; 59(5): 1254-60.
19. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2010; 54(1): 25-31.
20. Yang XL, Ma RC, Chan JC. Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Diabetologia 2011; 54(3): 709-10.
21. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-5.
22. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9): 1620-5.
23. Ioannou GN, Boyko EJ. Metformin and colorectal cancer risk in diabetic patients. Diabetes Care 2011; 34(10): 2336-7.
24. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3(11): 1451-61.
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52(9): 1766-77.
26. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-8.
27. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46(4): 279-84.
28. Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010; 90(3): 343-51.
29. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010; 53(8): 1631-7.
30. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25(6): 971-1010.
31. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49(11): 1603-16.
32. Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH. Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci 2010; 101(1): 65-72.
33. Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q, et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 2008; 15(2): 597-607.
34. Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW, et al. Low HDL cholesterol, metformin use and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011; 34(2): 375-80.
35. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-5.
36. Yang X, Ma RC, So WY, Yu LW, Kong AP, Ko GT, et al. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer 2011; 117(4): 862-71.
37. Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H, et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract 2010; 87: 117-25.
38. Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol 2010; 9: 77.
39. Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009; 32(10): 1826-32.
40. Yang XL, Ma RC, So WY, Kong APS, Xu G, Chan JCN. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong diabetes registry. The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy); 2011 2-5th June 2011 Shanghai, China 2011.
41. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15(4): 158-61.
42. Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, et al. Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 2009; 58(7): 1518-25.
43. Sui Y, Zhao HL, Ma RC, Ho CS, Kong AP, Lai FM, et al. Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci 2007; 64(23): 3119-28.
44. Zhao HL, Sui Y, Guan J, He L, Zhu X, Fan RR, et al. Fat redistribution and adipocyte transformation in uninephrectomized rats. Kidney Int 2008; 74(4): 467-77.
45. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9(8): 563-75.
46. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412(2): 211-21.
47. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8(12): 915-28.
48. Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res 2010; 70(1): 4-7.
49. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100(3): 328-41.
50. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114(1): 63-70.
51. Yang X, Ma RC, Chan JC. Response to comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in Type 2 diabetes: The Hong Kong Diabetes Registry. Diabetes;59:1254-1260. Diabetes 2010; 59: e19-e22.
52. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302(2): 128-39.
53. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003; 163(11): 1296-304.
54. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99(7): 1006-12.
55. Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 2009; 8(2): 189-97.
56. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010; 10(11): 745-59.
57. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179-84.
58. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011; 183(14): E1073-84.
59. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2010; 12(1): 65-82.
60. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138, 769 individuals. J Hypertens 2011; 29(4): 623-35.
61. Lindholm LH, Carlberg B. Blood-pressure drugs and cancer: much ado about nothing? Lancet Oncol 2010; 12(1): 6-8.
62. Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011; 29(22): 3001-7.
63. Yang X, Chan JC. Are large sample size studies the answer to evaluate effects of drug use in non-clinical trial settings? J Clin Oncol 2011; 29(33): 4464-5.
64. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2(7): 247-57.
65. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer-an unsubstantiated allegation. Diabetes Technol Ther 2009; 11(8): 473-6.
66. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 1999; 96(24): 13656-61.
67. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89(3): 331-40.
68. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103(4): 825-37.
69. Vigil D, Cherfils J, Rossman KL, Der CJ. RAS superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010; 10(12): 842-57.
70. Palozza P, Colangelo M, Simone R, Catalano A, Boninsegna A, Lanza P, et al. Lycopene induces cell growth inhibition by altering mevalonate pathway and RAS signaling in cancer cell lines. Carcinogenesis 2010; 31(10): 1813-21.
71. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52(9): 1732-44.
72. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55(1): 51-62.
73. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011; 34(9): 1965-71.
74. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44(15): 2122-32.
75. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136(5): 1601-8.
76. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009; 104(5): 1241-8.
77. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001; 22(22): 2075-84.
78. Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep 2006; 8(2): 139-43.
79. Haddad GE, Blackwell K, Bikhazi A. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist. Can J Physiol Pharmacol 2003; 81(2): 142-9.
80. Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol 2011, DOI: 101093/annonc/mdr540.
81. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107(1): 46-52.
82. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580-91.
83. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009; 32(6): 977-82.